Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled …
EM Apperloo, BL Neuen, RA Fletcher… - The Lancet Diabetes & …, 2024 - thelancet.com
Background SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and
kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the …
kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the …
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic …
BL Neuen, RA Fletcher, L Heath, A Perkovic… - Circulation, 2024 - ahajournals.org
BACKGROUND: GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-
glucose cotransporter 2) inhibitors both improve cardiovascular and kidney outcomes in …
glucose cotransporter 2) inhibitors both improve cardiovascular and kidney outcomes in …
Barriers to early diagnosis of chronic kidney disease and use of sodium‐glucose cotransporter‐2 inhibitors for renal protection: a comprehensive review and call to …
L Czupryniak, O Mosenzon, I Rychlík… - Diabetes, Obesity …, 2024 - Wiley Online Library
Chronic kidney disease (CKD) affects approximately 13% of people globally, including 20%–
48% with type 2 diabetes (T2D), resulting in significant morbidity, mortality, and healthcare …
48% with type 2 diabetes (T2D), resulting in significant morbidity, mortality, and healthcare …
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, N Staplin, KJ Mayne, C Wanner… - The Lancet Diabetes & …, 2024 - thelancet.com
Summary Background The EMPA-KIDNEY trial showed that empagliflozin reduced the risk
of the primary composite outcome of kidney disease progression or cardiovascular death in …
of the primary composite outcome of kidney disease progression or cardiovascular death in …
Long-term effects of empagliflozin in patients with chronic kidney disease
EMPA-KIDNEY Collaborative … - New England Journal of …, 2024 - Mass Medical Soc
Abstract Background In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose
cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic …
cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic …
Diabetic Kidney Disease—Semaglutide Flows into the Mainstream
WG Herrington, R Haynes - New England Journal of Medicine, 2024 - Mass Medical Soc
Chronic kidney disease is common and is associated with an increased risk of
cardiovascular disease and progression to kidney failure. It has many causes, of which …
cardiovascular disease and progression to kidney failure. It has many causes, of which …
SGLT2 inhibitors and kidney outcomes across the spectrum of kidney disease: a systematic review and meta-analysis
BF Spiazzi, GF Piccoli, LF Wayerbacher… - Clinical Journal of the …, 2024 - journals.lww.com
Background: SGLT2 inhibitors have shown to reduce clinically meaningful kidney outcomes
in individuals with chronic kidney disease at high risk for adverse outcomes. The effect of …
in individuals with chronic kidney disease at high risk for adverse outcomes. The effect of …
[HTML][HTML] Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant …
Background: This systematic review and meta-analysis aimed to evaluate the efficacy and
safety of novel antidiabetics, namely, sodium-glucose transport protein 2 inhibitors (SGLT2-i) …
safety of novel antidiabetics, namely, sodium-glucose transport protein 2 inhibitors (SGLT2-i) …
A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population
Background Observational studies suggest sodium-glucose co-transporter 2 (SGLT2)
inhibitor kidney outcome trials are not representative of the broader population of people …
inhibitor kidney outcome trials are not representative of the broader population of people …
Effects of sacubitril/valsartan across the spectrum of renal impairment in patients with heart failure
Abstract Background The Kidney Disease Improving Global Outcomes (KDIGO)
classification integrates both estimated glomerular filtration rate and urine-albumin …
classification integrates both estimated glomerular filtration rate and urine-albumin …